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Summary
Background Mutations in the gene encoding the bone morphogenetic protein receptor type II (BMPR2) are the 
commonest genetic cause of pulmonary arterial hypertension (PAH). However, the eﬀ ect of BMPR2 mutations on 
clinical phenotype and outcomes remains uncertain.
Methods We analysed individual participant data of 1550 patients with idiopathic, heritable, and anorexigen-associated 
PAH from eight cohorts that had been systematically tested for BMPR2 mutations. The primary outcome was the 
composite of death or lung transplantation. All-cause mortality was the secondary outcome. Hazard ratios (HRs) for 
death or transplantation and all-cause mortality associated with the presence of BMPR2 mutation were calculated 
using Cox proportional hazards models stratiﬁ ed by cohort.
Findings Overall, 448 (29%) of 1550 patients had a BMPR2 mutation. Mutation carriers were younger at diagnosis 
(mean age 35·4 [SD 14·8] vs 42·0 [17·8] years), had a higher mean pulmonary artery pressure (60·5 [13·8] vs 
56·4 [15·3] mm Hg) and pulmonary vascular resistance (16·6 [8·3] vs 12·9 [8·3] Wood units), and lower cardiac index 
(2·11 [0·69] vs 2·51 [0·92] L/min per m²; all p<0·0001). Patients with BMPR2 mutations were less likely to respond to 
acute vasodilator testing (3% [10 of 380] vs 16% [147 of 907]; p<0·0001). Among the 1164 individuals with available 
survival data, age-adjusted and sex-adjusted HRs comparing BMPR2 mutation carriers with non-carriers were 1·42 
(95% CI 1·15–1·75; p=0·0011) for the composite of death or lung transplantation and 1·27 (1·00–1·60; p=0·046) for 
all-cause mortality. These HRs were attenuated after adjustment for potential mediators including pulmonary 
vascular resistance, cardiac index, and vasoreactivity. HRs for death or transplantation and all-cause mortality 
associated with BMPR2 mutation were similar in men and women, but higher in patients with a younger age at 
diagnosis (p=0·0030 for death or transplantation, p=0·011 for all-cause mortality).
Interpretation Patients with PAH and BMPR2 mutations present at a younger age with more severe disease, and are 
at increased risk of death, and death or transplantation, compared with those without BMPR2 mutations.
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Introduction
Pulmonary arterial hypertension (PAH) is a rare disorder 
characterised by progressive remodelling of the small 
pulmonary arteries resulting in increased pulmonary 
vascular resistance and ultimately right ventricular 
failure and death.1,2 The diagnosis of PAH requires a 
mean pulmonary artery pressure of 25 mm Hg or more 
with a pulmonary artery wedge pressure of 15 mm Hg or 
less at right heart catheterisation in the absence of 
chronic thromboembolic, left heart, or respiratory 
disease.3 The classiﬁ cation of PAH includes idiopathic 
and heritable forms. Additionally, PAH might occur after 
drug or toxin exposure (eg, anorexigens) or in association 
with other conditions such as congenital heart disease, 
connective tissue disease, liver disease, or HIV infection.4
In 2000, heterozygous germline mutations in the gene 
encoding the bone morphogenetic protein receptor 
type II (BMPR2) were identiﬁ ed as the main genetic 
cause of familial PAH.5,6 Over 300 diﬀ erent BMPR2 
mutations have been identiﬁ ed with a prevalence of 
greater than 75% in families with PAH.7,8 BMPR-II is a 
receptor for the bone morphogenetic proteins (members 
of the transforming growth factor-β superfamily). 
Mutations in the BMPR2 gene cause loss-of-function and 
reduced signalling downstream of the receptor. 
Subsequently, BMPR2 mutations have been identiﬁ ed in 
apparently sporadic cases of idiopathic PAH with a 
frequency ranging from 11%9 to 40%.10 The occurrence of 
BMPR2 mutations in sporadic PAH cases in the absence 
of a family history can be accounted for by the relatively 
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low penetrance of BMPR2 mutations (20–30%) and the 
occurrence of de novo mutations.11
Recent European guidelines for the management of 
PAH recommend oﬀ ering genetic counselling and 
screening for BMPR2 mutations to patients diagnosed 
with idiopathic, heritable, and anorexigen-associated 
PAH, mainly to enable predictive genetic testing of 
relatives.12 Studies have suggested that patients with 
PAH carrying causal BMPR2 mutations present at an 
earlier age with more severe haemodynamic 
compromise.13–17 Although this might be expected to 
confer a worse survival, robust evidence describing the 
eﬀ ect of BMPR2 mutations on long-term outcomes in 
these patients is lacking, primarily due to the limited 
power of individual studies and survival bias.18,19
We established the BMPR2 Studies Collaboration to 
investigate the eﬀ ect of BMPR2 mutations on clinical 
phenotypes and long-term outcomes in patients with 
PAH. This international consortium has allowed central 
collation and harmonisation of participant data on 
1550 patients with PAH from eight cohorts based in six 
diﬀ erent countries.
Methods
Data sources
We sought individual participant data from studies 
identiﬁ ed through systematic searches of the published 
literature using MEDLINE and Embase (search terms 
“BMPR2” and “pulmonary hypertension”, up to March 
18, 2014), searches of conference proceedings (restricted 
to the English language), and discussions with 
investigators. Cohort studies were eligible for inclusion if 
they met the following criteria: included patients with 
idiopathic PAH, heritable PAH, or anorexigen-associated 
PAH; sequenced patients for BMPR2 mutations; 
recorded baseline information on demographic and 
haemodynamic data at diagnosis, and for analysis of 
survival, recorded information on outcomes (death or 
transplantation). Inclusion of patients recruited to 
cohorts and registries since publication of original 
manuscripts was provided where available, including 
updated survival data. Details of contributing cohorts are 
presented in the appendix. Data from each study were 
obtained using a standardised spreadsheet; raw data 
were examined, and inconsistencies or irregularities 
were clariﬁ ed with the relevant investigators.
Ethical approval was obtained for each of the individual 
studies included in this analysis and all participants 
provided informed written consent. This study followed 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses of Individual Participants Data 
(PRISMA-IPD) guidelines (checklist available in the 
appendix).20
Study participants
All contributing studies used international criteria for 
the diagnosis of PAH.21 For the purpose of this study, the 
expert physician diagnosis of idiopathic PAH, heritable 
PAH, or anorexigen-associated PAH in a specialist centre 
was suﬃ  cient and data pertaining to the full range of 
investigations at diagnosis were not collected.
Vasodilator responsiveness was deﬁ ned as a reduction 
in mean pulmonary arterial pressure of at least 10 mm Hg 
to a level below 40 mm Hg with no reduction in cardiac 
output after administration of inhaled nitric oxide, 
although some centres have historically used inhaled 
prostacyclin or intravenous prostacyclin, according to 
local practice. Treatment for PAH was prescribed 
Research in context
Evidence before this study
In the year 2000, mutations in the BMPR2 gene were identiﬁ ed as 
the major genetic cause of pulmonary arterial hypertension 
(PAH). Some small studies have examined the eﬀ ect of BMPR2 
mutations on the presentation, haemodynamic proﬁ le, and 
outcomes in patients with PAH. These studies suggested that 
those with BMPR2 mutations present at a younger age with more 
severe derangements of cardiopulmonary haemodynamics. Due 
to a lack of statistical power, lack of adjustment for important 
factors such as age and sex, and confounding from inclusion of 
prevalent cases without necessary adjustments in many of these 
studies, the eﬀ ect of BMPR2 mutations on long-term outcomes 
has not been reliably established.
Added value of this study
By harmonising individual participant data from 1550 patients 
in eight published and unpublished studies, with updated 
follow-up, this study provides the most deﬁ nitive assessment 
of the eﬀ ect of BMPR2 mutations on the haemodynamic 
proﬁ le at diagnosis and long-term outcomes in patients with 
PAH. This study has shown that possession of a BMPR2 
mutation is associated with an increased risk of death or 
transplantation and all-cause mortality. This association 
appears to be mediated by a more severe haemodynamic 
proﬁ le measured at diagnosis with the greatest proportion of 
the risk accounted for by the lower cardiac index in BMPR2 
mutation carriers. There was a strong interaction between the 
eﬀ ect of a BMPR2 mutation and age at diagnosis, such that the 
increased risk of death or transplantation and all-cause 
mortality associated with possession of a BMPR2 mutation was 
greater in younger patients.
Implications of all the available evidence
Patients with PAH with underlying BMPR2 mutations are 
younger at diagnosis, have more severe disease, and have a 
worse prognosis than patients without BMPR2 mutations. 
The role of routine genetic testing for BMPR2 mutations on the 
management of patients with PAH deserves further study. 
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consistent with prevailing international guidelines at the 
time of recruitment, at the discretion of the clinical team 
in each institution. Data regarding initial and subsequent 
PAH targeted therapy were not available for this analysis. 
Cohorts comprised a combination of incident patients, 
deﬁ ned for the purposes of this study as those who were 
enrolled in their respective study and thus committed to 
genotyping within 6 months of PAH diagnosis, and 
prevalent patients who were enrolled more than 6 months 
after PAH diagnosis.
Patients were excluded from the analysis if they had 
PAH associated with conditions such as connective 
tissue disease, HIV, congenital heart disease, or portal 
hypertension. Furthermore, to avoid potential 
confounding from mutations in other genes or 
undetected BMPR2 mutations, patients with a family 
history of PAH but with no identiﬁ able BMPR2 mutation 
were also excluded. Patients with a history of anorexigen 
exposure were included since BMPR2 mutations have 
been recorded in these patients, and the disease is 
indistinguishable from idiopathic PAH.4,22
Outcomes
The primary outcome was the composite of death or lung 
transplantation. All-cause mortality was the secondary 
outcome. Patients contributed only the ﬁ rst outcome 
recorded during follow-up (ie, deaths preceded by 
transplantation were not included) because data 
regarding post-transplant survival were not available. 
Outcomes were censored if a patient was lost to follow-
up or reached the end of the follow-up period. In analysis 
of all-cause mortality, patients were censored at the time 
of transplantation. Date of PAH diagnosis was deﬁ ned as 
the date of diagnostic right heart catheterisation.
Statistical analysis
Baseline characteristics of patients according to BMPR2 
mutation status were compared using t test for 
continuous variables and χ² test for categorical variables. 
Associations of BMPR2 mutation status with risk of 
death or transplantation and all-cause mortality recorded 
during follow-up were assessed using Cox proportional 
hazards regression models stratiﬁ ed by cohort and 
timing of study entry (ie, incident or prevalent). We used 
a one-stage stratiﬁ ed model rather than two-stage 
random eﬀ ects model for our primary analysis because 
of the small number of participants in some studies. As 
a sensitivity analysis, we pooled data using a two-stage 
random eﬀ ects model and assessed for heterogeneity 
between studies by calculating the I² statistic and 
assessed statistical signiﬁ cance based on Cochran’s 
Q test p value. Unless stated otherwise, hazard ratios 
(HRs) were adjusted for age at diagnosis and sex. The 
proportional hazards assumption was satisﬁ ed for the 
composite of death or transplantation and all-cause 
mortality. Survival curves comparing patients with and 
without BMPR2 mutations were calculated using 
unadjusted Kaplan-Meier estimates and compared using 
the log-rank test.
To restrict the scope for potential bias due to inclusion 
of prevalent patients (ie, those diagnosed with PAH more 
than 6 months before study enrolment), Cox proportional 
hazards regression models and survival curves were 
ﬁ tted allowing for left truncation arising from the interval 
between diagnosis and enrolment. These patients were 
only included in the risk set from the time of study entry 
and were excluded if they entered the study more than 
10 years after diagnosis. In patients for whom the date of 
enrolment in the study was not available, patients entered 
the risk set on the date they were genotyped for BMPR2 
mutations. Given that worse survival has been reported 
in incident patients compared with prevalent patients in 
Figure 1: Study and patient selection
297 references identified on MEDLINE
370 references identified on Embase
437 references screened
21 references reporting 10 studies
2 studies excluded
 1 no response from authors
 1 had only patients <16 years
1612 patients with data from eight studies
1550 patients included in the analysis of
  demographics and haemodynamics
1310 patients from six studies potentially eligible 
 for survival  analysis
1164 patients included in the survival analysis
62 patients excluded
 45 no detected BMPR2 mutation in 
  patients with a family history
 13 not idiopathic or familial PAH
 3 KCNK3 mutation
 1 no BMPR2 mutation status
240 patients excluded (data from two 
 studies)
146 patients excluded
 85 greater than 10 years between 
  diagnosis and study enrolment
 41 last follow-up or event before 
  study entry
 20 missing data on data of diagnosis, 
  date of study entry, or outcome
230 duplicates removed
403 references excluded based on review
 of title and abstract
34 articles were selected for full text review
15 articles excluded after full text review
 11 clinical or outcome data not 
  reported
 2 review articles
 2 population not systematically
  screened for BMPR2 mutations
2 references from other sources
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observational studies,18 and a higher risk of PAH-related 
death or admission to hospital was reported in incident 
patients in a clinical trial population,23 Cox models were 
also stratiﬁ ed by timing of study entry. Data pertaining to 
familial clustering of individuals and mutations were not 
available; however, to account for this, survival models 
were adjusted for clustering by sets of individuals with 
the same mutation from the same cohort. Two studies 
were not included in the survival analysis (due to 
insuﬃ  cient survival data) but were included in the 
description of demographic and haemodynamic 
characteristics.
We explored interactions between the eﬀ ect of BMPR2 
mutation with age at diagnosis and sex within the one-
stage stratiﬁ ed Cox models. The interaction with age at 
diagnosis was assessed with age as a continuous variable, 
with cases separated into three post-hoc groups according 
to age at diagnosis for illustrative purposes (<30 years, 
30–50 years, and >50 years).
To assess the degree to which the association of 
BMPR2 mutations with outcome was mediated by 
haemodynamic characteristics at diagnosis, we 
calculated the percentage of excess risk mediated 
(PERM) by three mediators thought likely to be in the 
causal pathway: pulmonary vascular resistance, cardiac 
index, and vasodilator responsiveness. Each of these 
mediators was added to the age-adjusted and sex-
adjusted Cox proportional hazards models individually, 
and then all three simultaneously. The PERM, that is the 
degree to which the HR is attenuated by addition of the 
mediator in question, was calculated using the equation:
For this analysis, missing covariate data were imputed 
using multiple imputation by chained equations in those 
individuals included in the survival analysis, to generate 
ten datasets with complete covariates. Cox proportional 
hazards models were ﬁ tted within each imputed dataset 
and combined using Rubin’s rules. This analysis was 
repeated using only cases that had complete data for all 
three mediators as a sensitivity analysis.
In an exploratory analysis, we compared haemodynamic 
parameters at presentation (compared using one-way 
ANOVA) and survival in patients by BMPR2 mutation 
type. Mutations were assigned to one of ﬁ ve categories 
(frameshift, stop-gained, splice site or intronic, large 
deletions or exonal duplications, missense).
A two-sided p value less than 0·05 was considered 
statistically signiﬁ cant throughout. Statistical analyses 
were done using Stata (version 14; StataCorp, College 
Station, TX, USA).
Role of the funding source
No funding bodies had any role in the design, conduct, 
analysis of this study, or writing of the manuscript. The 
corresponding author had full access to the data and had 
the ﬁ nal responsibility for the decision to submit this 
manuscript with the permission of all coauthors.
Results
Figure 1 shows the inclusion and exclusion of studies and 
patients. Of ten studies identiﬁ ed, one eligible cohort 
(that involved 61 patients and was available only in 
abstract form)24 did not contribute data to the current 
analysis, and one cohort was excluded because it 
exclusively included 47 patients younger than 16 years.25 
We analysed data from a total of 1550 patients with 
idiopathic, heritable, and anoroxigen-associated PAH 
from eight cohorts (appendix).13–17,26–28 The mean age 
at diagnosis was 40·1 (SD 17·2) years, 72% 
(1105/1545 [data for ﬁ ve patients were unavailable]) were 
women, 60% (931/1550) were from western Europe, 18% 
(276/1550) from North America, and 22% (343/1550) 
from east Asia. Overall, 448 (29%) of 1550 patients had an 
identiﬁ ed BMPR2 mutation and 86 (6%) of 1550 patients 
had a recorded history of anorexigen exposure. 
Histograms of the dates during which patients included 
in the survival analyses were diagnosed and recruited into 
these studies are shown in the appendix.
All patients BMPR2 mutation status
Non-carriers 
(N=1102)
Carriers (N=448) p value
Age at diagnosis (N=1447), 
years
40·1 (17·2) 42·0 (17·8) 35·4 (14·8) <0·0001
Male sex 440/1545 (28%) 302/1097 (28%) 138/448 (31%) 0·20
Family history of PAH 202/1376 (15%) ·· 202/402 (50%) ··
Body-mass index (N=1206), 
kg/m²
24·9 (9·1) 24·9 (10·6) 24·9 (5·9) 0·99
6-min walk distance 
(N=1072), m
378 (124) 374 (128) 388 (113) 0·088
NYHA functional class 0·38
I–II 423/1426 (30%) 313/1031 (30%) 110/394 (28%)
III 896/1426 (63%) 647/1031 (63%) 249/394 (63%)
IV 107/1426 (8%) 72/1031 (7%) 35/394 (9%)
Mean pulmonary artery 
pressure (N=1503), mm Hg
57·6 (15·0) 56·4 (15·3) 60·5 (13·8) <0·0001
Pulmonary vascular 
resistance (N=1300), Wood 
units
14·0 (8·4) 12·9 (8·3) 16·6 (8·3) <0·0001
Right atrial pressure 
(N=1253), mm Hg
8·2 (5·5) 8·0 (5·7) 8·6 (5·2) 0·065
Cardiac output (N=1202), 
L/min
3·98 (1·44) 4·20 (1·50) 3·50 (1·17) <0·0001
Cardiac index (N=1358), 
L/min per m²
2·40 (0·88) 2·51 (0·92) 2·11 (0·69) <0·0001
Vasodilator responder 157/1287 (12%) 147/907 (16%) 10/380 (3%) <0·0001
Data are n/N (%) or mean (SD), unless otherwise stated. PAH=pulmonary arterial hypertension. NYHA=New York Heart 
Association. 
Table 1: Demographics and clinical measurements at diagnosis
HRwithout mediator – HRwith mediator 
 HRwithout mediator – 1
 × 100
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The proportion of patients with BMPR2 mutations 
varied between studies (appendix). In patients with no 
recorded family history of PAH, a BMPR2 mutation was 
identiﬁ ed in 17% (200/1174), whereas in patients with a 
family history of PAH a mutation was identiﬁ ed in 82% 
(202/247). Patients with a BMPR2 mutation were 
younger at diagnosis (mean age 35·4 years vs 42·0 years, 
p<0·0001) and the proportion of patients with a BMPR2 
mutation was greater in those diagnosed at a younger 
age (37% [162/434] in those aged <30 years, 33% 
[187/562] in those aged 30–50 years, and 17% [75/451] in 
those aged >50 years at diagnosis; p<0·0001). A 
comparison of haemodynamic and functional 
parameters measured at the time of diagnosis between 
carriers and non-carriers of a BMPR2 mutation is 
shown in table 1. Those carrying a BMPR2 mutation 
Figure 2: Kaplan-Meier survival curves according to BMPR2 mutation status
(A) Transplant-free survival, all patients (p=0·0016). (B) Overall survival, all patients (p=0·32). (C) Transplant-free survival, younger than 50 years at diagnosis 
(p<0·0001). (D) Overall survival, younger than 50 years at diagnosis (p=0·0032). (E) Transplant-free survival, older than 50 years at diagnosis (p=0·27). (F) Overall 
survival, 50 years or older at diagnosis (p=0·16). Survival curves are not adjusted for age at diagnosis or sex and are not stratiﬁ ed by study cohort.
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had a higher mean pulmonary artery pressure and 
pulmonary vascular resistance, and lower cardiac index. 
No diﬀ erence was recorded in the severity of symptoms 
assessed by New York Heart Association functional 
class or exercise capacity assessed by 6 min walk 
distance. Patients with a BMPR2 mutation were less 
likely to respond to acute vasodilator testing (table 1).
Characteristics of the 1164 patients from the six studies 
that contributed to the survival analysis are shown in the 
appendix. Survival curves by BMPR2 mutation status in 
the combined dataset are shown in ﬁ gure 2. Of the 
1164 patients, 723 (62%) were incident cases and 
441 (38%) were prevalent cases. The median interval 
between diagnosis and study entry in the prevalent 
patients was 1·8 years (IQR 1·1–4·5). During 
5870 person-years at risk (median duration of follow-up 
from diagnosis 5·4 years [IQR 3·0–8·2]), there were 
354 deaths and 74 patients underwent lung 
transplantation. Age-adjusted and sex-adjusted HRs 
comparing BMPR2 mutation carriers with non-carriers 
were 1·42 (95% CI 1·15–1·75; p=0·0011) for the 
composite of death or lung transplantation and 1·27 
(1·00–1·60; p=0·046) for all-cause mortality (table 2). 
HRs were unchanged after adjusting for previous 
exposure to anorexigens. Addition of each of the three 
mediators assessed to the age-adjusted and sex-adjusted 
models attenuated the HRs associated with BMPR2 
mutation for both death or transplantation and all-cause 
mortality (table 2). Cardiac index mediated the greatest 
proportion of excess risk, accounting for 65% and 79% of 
the increased HR for death or transplantation and all-
cause mortality, respectively. The PERM by the 
combination of pulmonary vascular resistance, cardiac 
index, and vasodilator responsiveness was 71% for death 
or transplantation and 100% for all-cause mortality. In 
the complete case sensitivity analysis (913 patients; 
appendix) the PERM by each mediator was similar.
HRs associated with possession of a BMPR2 mutation 
were similar in men and women (p=0·576 for death or 
transplantation, p=0·636 for all-cause mortality), but 
higher in patients with a younger age at diagnosis 
(p=0·0030 for death or transplantation, p=0·011 for all-
cause mortality; ﬁ gure 3, appendix). The interaction of 
BMPR2 and age at diagnosis persisted after adjustment 
for potential mediators (appendix).
Similar results were recorded with meta-analysis using 
a two-stage approach with random eﬀ ects (appendix). 
Between-study heterogeneity was modest, both for death 
or transplantation (I²=36·9% [95% CI 0–70]; p=0·16) and 
all-cause mortality (I²=20·1% [0–65]; p=0·28).
There were no signiﬁ cant diﬀ erences in haemodynamic 
parameters at diagnosis between those with diﬀ erent 
mutation subtypes (appendix). Patients with missense 
mutations were slightly younger at diagnosis. No 
signiﬁ cant diﬀ erence was recorded in the risk of death or 
transplantation or all-cause mortality among carriers of 
diﬀ erent types of BMPR2 mutations (appendix).
Discussion
To our knowledge, this meta-analysis of individual 
participant data from published and unpublished studies 
provides the most comprehensive standardised 
assessment of associations of BMPR2 mutations with 
long-term outcomes in patients with idiopathic, heritable, 
and anorexigen-associated PAH.
We have shown that patients diagnosed with PAH have 
an increased risk of death or transplantation and all-
cause mortality if they possess a mutation in the BMPR2 
gene. HRs associated with possession of a BMPR2 
mutation were similar in males and females, but greater 
with younger age at diagnosis. Furthermore, we have 
conﬁ rmed in this analysis the previously reported 
observations that patients with BMPR2 mutations 
present at a younger age, have more severe 
haemodynamic compromise at diagnosis with higher 
mean pulmonary artery pressure and pulmonary vascular 
HR (95% CI) for BMPR2 
mutation
p value PERM
Death or transplantation
Pulmonary vascular resistance
Adjusted for age and sex 1·42 (1·15–1·75) 0·0011
Adjusted for age, sex, and pulmonary vascular 
resistance
1·28 (1·03–1·58) 0·024 34%
Cardiac index
Adjusted for age and sex 1·42 (1·15–1·75) 0·0011
Adjusted for age, sex, and cardiac index 1·18 (0·95–1·47) 0·14 65%
Vasoreactivity
Adjusted for age and sex 1·42 (1·15–1·75) 0·0011
Adjusted for age, sex, and vasoreactivity 1·26 (1·02–1·57) 0·036 37%
Combined model
Adjusted for age and sex 1·42 (1·15–1·75) 0·0011
Adjusted for age, sex, pulmonary vascular resistance, 
cardiac index, and vasoreactivity
1·12 (0·89–1·41) 0·33 71%
All-cause mortality
Pulmonary vascular resistance
Adjusted for age and sex 1·27 (1·00–1·60) 0·046
Adjusted for age, sex, and pulmonary vascular 
resistance
1·13 (0·89–1·43) 0·33 53%
Cardiac index
Adjusted for age and sex 1·27 (1·00–1·60) 0·046
Adjusted for age, sex, and cardiac index 1·06 (0·83–1·35) 0·67 79%
Vasoreactivity
Adjusted for age and sex 1·27 (1·00–1·60) 0·046
Adjusted for age, sex, and vasoreactivity 1·14 (0·89–1·45) 0·29 49%
Combined model
Adjusted for age and sex 1·27 (1·00–1·60) 0·046
Adjusted for age, sex, pulmonary vascular resistance, 
cardiac index, and vasoreactivity
1·00 (0·77–1·29) 0·98 100%
Hazard ratios (HRs) associated with possession of a BMPR2 mutation after addition of each mediator individually to 
age-adjusted and sex-adjusted Cox proportional hazards models with the percentage of excess risk mediated (PERM) 
by each mediator. Missing data for mediators generated by multiple imputation.
Table 2: Proportion of excess risk mediated by haemodynamic variables at diagnosis
Articles
www.thelancet.com/respiratory   Vol 4   February 2016 135
resistance and lower cardiac index, and are less likely to 
respond to acute vasodilator testing and more likely to 
undergo lung transplantation.13–17,26
The precise mechanisms underlying the diﬀ erence in 
survival in those with a BMPR2 mutation remain unclear. 
We have found that after adjusting for pulmonary 
vascular resistance, cardiac index, and vasodilator 
responsiveness, HRs for death or lung transplantation 
and all-cause mortality were attenuated. The low number 
of BMPR2 mutation carriers having vasodilator 
responsiveness, a phenotype associated with a good 
prognosis when treated with calcium-channel blocker 
therapy,29,30 is consistent with a predominance of extensive 
vascular remodelling rather than vasoconstriction. Given 
that the greatest percentage of the excess risk associated 
with a BMPR2 mutation was accounted for by reduced 
cardiac index at diagnosis, impaired right ventricular 
adaptation to increased afterload in those with BMPR2 
mutations could be an important factor, as has been 
suggested in preclinical studies.31
Our ﬁ nding of a greater proportion of BMPR2 mutations 
in younger age groups is consistent with the common 
observation that diseases with a major genetic contribution 
tend to present with an earlier onset. The strong interaction 
between BMPR2 mutation status and age at diagnosis is of 
great interest and has not been reported before. Patients 
carrying a BMPR2 mutation in which PAH manifests at a 
younger age might have a more severe mutation that not 
only results in more extensive pulmonary vascular 
remodelling or impaired right ventricular adaptation at 
diagnosis, but also results in more rapid progression of the 
disease process. This hypothesis is supported by the 
observation that the worse prognosis associated with a 
BMPR2 mutation in patients diagnosed before the age of 
30 years in this study was not completely attenuated after 
adjustment for pulmonary vascular resistance, cardiac 
index, and vasoreactivity.
Data from the UK PAH registry32 suggest that patients 
with PAH diagnosed after the age of 50 years are 
phenotypically distinct compared with younger patients. 
Older patients have a higher prevalence of cardiovascular 
comorbidities including systemic hypertension, atrial 
ﬁ brillation, and diabetes. In the present study, although 
we did not collect data on comorbidities, we found that 
the proportion of patients with a BMPR2 mutation is 
lower in those diagnosed after the age of 50 years than in 
younger patients. Additionally, we show that after 
adjusting for age and sex, mutations do not aﬀ ect survival 
in these older patients, and prognosis might even be 
better in those with mutations. BMPR2 mutations 
present in those who do not develop PAH until later in 
life might be less deleterious. Alternatively, in the older 
age group, comorbidities might outweigh the eﬀ ect of 
BMPR2 mutations on survival.
Our study conﬁ rms the relatively high frequency of 
BMPR2 mutations in idiopathic and heritable PAH, and 
supports a central role for the BMPR2 pathway in the 
initiation of this disease. Moreover, the eﬀ ect of BMPR2 
mutation on survival suggests a role for BMPR-II 
dysfunction in the clinical progression of the disease. 
Both of these observations support further investigations 
into the potential targeting of the BMPR-II pathway for 
therapeutic intervention in PAH.33,34
The main reason to test for the presence or absence of 
a BMPR2 mutation in a patient with PAH is to guide 
predictive genetic testing in unaﬀ ected relatives. 
Although our ﬁ ndings show that BMPR2 mutations are 
associated with a worse survival, the usefulness of this 
result for prognostic purposes might be restricted in the 
clinic, since the majority of this risk appears to be 
accounted for by the known haemodynamic predictors of 
mortality measured during the diagnostic assessment 
during right heart catheterisation. Despite this, in 
younger patients, in which the increased risk appears to 
persist after adjustment for these factors, albeit only in 
subgroup analyses, screening for mutations might add 
value, and this warrants further investigation.
Our analysis has major strengths. We had access to 
data for more than 95% of participants from eligible 
cohorts. We analysed individual participant data to avoid 
limitations of literature-based reviews. We had 
information on both all-cause mortality and death or 
transplantation. We studied clinically relevant 
subpopulations (such as by age and sex) reliably, 
exploiting the study’s considerable statistical power. We 
avoided potential over-adjustment in the primary 
analysis by not adjusting for variables (eg, pulmonary 
Figure 3: Hazard ratios (HRs) for the eﬀ ect of a BMPR2 mutation on death or transplantation and all-cause 
mortality by age at diagnosis and sex
p value for interaction of BMPR2 and age at diagnosis calculated with age at diagnosis as a continuous variable.
Age at diagnosis (years)
<30
30–50
>50
Sex
Male
Female
344
441
379
345
819
144
137
147
153
275
1·86 (1·30–2·68)
1·58 (1·13–2·22)
0·83 (0·55–1·27)
1·52 (1·09–2·13)
1·35 (1·04–1·76)
0·003
0·576
Death or transplantation
Age at diagnosis (years)
<30
30−50
>50
Sex
Male
Female
344
441
379
345
819
102
109
143
126
228
1·78 (1·17–2·72)
1·34 (0·93–1·95)
0·82 (0·53–1·26)
1·36 (0·94–1·98)
1·22 (0·91–1·63)
0·011
0·636
All-cause mortality
  0·5 1 2 3
HR (95% CI) for BMPR2 carrier
Number of
participants
Number of
events
HR (95% CI) p value for 
interaction
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vascular resistance, cardiac index, and vasoreactivity) 
that could mediate associations between BMPR2 and 
death or transplantation and all-cause mortality. We 
ensured generalisability by studying cohorts located 
across east Asia, Europe, and North America.
Our analysis has some limitations. Studies included 
diﬀ ered in their methods of recruitment and data 
collection, and in the proportion of familial cases and 
individuals with BMPR2 mutations, which might 
explain the heterogeneity recorded between studies. 
Nevertheless, we obtained similar results to those in our 
primary analysis based on a stratiﬁ ed Cox proportional 
hazards model when we used a two-stage random eﬀ ects 
meta-analysis model in sensitivity analysis. Additionally, 
given the evidence for interaction recorded between 
mutation status and age, the diﬀ erences in age at 
diagnosis in diﬀ erent studies could partly explain the 
heterogeneity recorded in two-stage meta-analyses. The 
inclusion of prevalent patients in survival analyses can 
introduce bias; however, we addressed this in the Cox 
proportional hazards model by allowing for left 
truncation arising from the interval between diagnosis 
and study entry and also stratifying by timing of 
enrolment. Additionally, we observed no interaction 
between BMPR2 mutation status and timing of 
enrolment. Finally, the lack of data regarding the timing 
and use of PAH-directed therapies might introduce 
some bias, although we believe any eﬀ ect is likely to be 
very small. Indeed, if patients with BMPR2 mutations 
were treated more aggressively due to their more severe 
haemodynamic derangements at diagnosis, this could 
have resulted in an attenuation of the association we 
have recorded.
By harnessing data from observational studies done 
worldwide, we have shown that in patients with 
idiopathic, familial, and anorexigen-associated PAH, the 
presence of a mutation in the BMPR2 gene is associated 
with an increased risk of death or lung transplantation 
and all-cause mortality, particularly in those diagnosed at 
a younger age. Our analysis suggests that this association 
is largely mediated by the more severe haemodynamic 
derangements and low frequency of vasodilator 
responsiveness at diagnosis seen in those with BMPR2 
mutations.
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